Defence Therapeutics (XCNQ:DTC) EBIT per Share : C$-0.27 (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Defence Therapeutics EBIT per Share?

Defence Therapeutics's EBIT per Share for the three months ended in Dec. 2023 was C$-0.19. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was C$-0.27.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Defence Therapeutics's EBIT per Share or its related term are showing as below:

XCNQ:DTC's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.6
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Defence Therapeutics's EBIT for the three months ended in Dec. 2023 was C$-8.26 Mil.

Defence Therapeutics EBIT per Share Historical Data

The historical data trend for Defence Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Defence Therapeutics EBIT per Share Chart

Defence Therapeutics Annual Data

Trend

Jun20

Jun21

Jun22

EBIT per Share

-0.02

-0.11

-0.20

Defence Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Sep23	Dec23
EBIT per Share	Get a 7-Day Free Trial										-0.05	-0.05	-0.03	-0.05	-0.19

Defence Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Defence Therapeutics's EBIT per Share for the fiscal year that ended in Jun. 2022 is calculated as

	EBIT per Share		(A: Jun. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-7.32	/	36.077
=	-0.20

Defence Therapeutics's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-8.262	/	44.098
=	-0.19

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.27

Defence Therapeutics (XCNQ:DTC) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Defence Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Defence Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Defence Therapeutics (XCNQ:DTC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Defence Therapeutics Inc (XCNQ:DTC) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

DTCFF:USA DTC:Germany

Address

200 Burrard Street, Suite 1680, Vancouver, BC, CAN, V6C3L6

Website

https://www.defencetherapeutics.com

Defence Therapeutics Inc is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The Company has one operating segment, being research and development.

Executives

Sarkis Meterissian

Director